Client Result
Orrick Advises Third Rock Ventures on Investment in CARGO Therapeutics
1 minute read | March.02.2023

The proceeds from the financing will be used to advance CARGO’s autologous CD22 CAR T-cell therapy candidate, CRG-022.
1 minute read | March.02.2023
The proceeds from the financing will be used to advance CARGO’s autologous CD22 CAR T-cell therapy candidate, CRG-022.
September.19.2022
June.04.2020